-
Mercati
athexgroup.grAthens Exchange GroupLeggi tuttoTogether for a unified, stronger European capital market.
-
Azioni
Sustainable finance2025 Euronext ESG Trends ReportLeggi tuttoA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indici
Access the white paperInvesting in the future of Europe with innovative indicesLeggi tuttoThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLeggi tuttoInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fondi
-
Obbligazioni
European Defence BondsGroupe BPCE lists the first bondLeggi tuttoFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Prodotti strutturati
-
Derivati
Where European Government Bonds Meet the FutureFixed Income derivativesLeggi tuttoTrade mini bond futures on main European government bonds
-
Commodities
- Panoramica
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Container Freight Futures
- Consegna e liquidazione
- Specifiche e disposizioni
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLeggi tuttoEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Documenti e risorse
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLeggi tuttoJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 04 Aug 2025 13:40 CEST |
BERGENBIO | BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jul 2025 14:53 CEST |
BERGENBIO | BerGenBio ASA: Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Jun 2025 22:30 CEST |
BERGENBIO | BerGenBio ASA - Key information related to the rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Jun 2025 22:05 CEST |
BERGENBIO | Announcement of fully underwritten rights issue | 20103010 Biotechnology | Inside information |
| 30 Jun 2025 22:00 CEST |
BERGENBIO | BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue | 20103010 Biotechnology | Inside information |
| 26 Jun 2025 11:29 CEST |
BERGENBIO | BerGenBio ASA - Minutes from the annual general meeting 2025 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jun 2025 19:22 CEST |
BERGENBIO | BerGenBio ASA: Update on Strategic Review Process and Status of Activities | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jun 2025 15:55 CEST |
BERGENBIO | BerGenBio ASA: Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2025 09:51 CEST |
BERGENBIO | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Apr 2025 22:03 CEST |
BERGENBIO | BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar | 20103010 Biotechnology | Annual financial and audit Reports |
| 26 Mar 2025 07:00 CET |
BERGENBIO | BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Mar 2025 07:00 CET |
BERGENBIO | BerGenBio announces advancement of its strategic review | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Feb 2025 07:00 CET |
BERGENBIO | BerGenBio Fourth Quarter Results 2024 | 20103010 Biotechnology | Inside information |
| 25 Feb 2025 19:58 CET |
BERGENBIO | BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives | 20103010 Biotechnology | Inside information |
| 25 Feb 2025 19:58 CET |
BERGENBIO | BerGenBio avslutter 1L STK11m NSCLC-studie og vil utforske strategiske alternativer | 20103010 Biotechnology | Innsideinformasjon |
| 24 Feb 2025 08:13 CET |
BERGENBIO | BerGenBio - Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 18 Feb 2025 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to fourth quarter 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Jan 2025 07:00 CET |
BERGENBIO | BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Dec 2024 14:33 CET |
BERGENBIO | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Nov 2024 08:00 CET |
BERGENBIO | BerGenBio to Present Company Update at DNB Nordic Healthcare Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Nov 2024 20:31 CET |
BERGENBIO | BerGenBio Appoints Olav Hellebø as CEO | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Nov 2024 07:00 CET |
BERGENBIO | BerGenBio Third Quarter Results 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Nov 2024 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to third quarter 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Oct 2024 21:31 CEST |
BERGENBIO | CEO Martin Olin steps down | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Oct 2024 11:07 CEST |
BERGENBIO | BerGenBio ASA: Minutes from Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Oct 2024 07:00 CEST |
BERGENBIO | BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Sep 2024 15:00 CEST |
BERGENBIO | BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Sep 2024 15:24 CEST |
BERGENBIO | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio Second Quarter Results 2024: Solid clinical and financial progress | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 20 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Aug 2024 09:57 CEST |
BERGENBIO | BerGenBio ASA: Registration of share capital reduction | 20103010 Biotechnology | Total number of voting rights and capital |
| 13 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Jul 2024 07:00 CEST |
BERGENBIO | BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Jun 2024 17:35 CEST |
BERGENBIO | BerGenBio ASA: Grant of share options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jun 2024 18:02 CEST |
BERGENBIO | BerGenBio ASA - Registration of reverse share split | 20103010 Biotechnology | Total number of voting rights and capital |
| 30 May 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA - Ex. reverse share split and change of ISIN today | 20103010 Biotechnology | Ex Date |
| 29 May 2024 07:00 CEST |
BERGENBIO | BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 15:11 CEST |
BERGENBIO | BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi® | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 14:00 CEST |
BERGENBIO | BerGenBio ASA - Key information relating to the reverse share split and change of ISIN | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 10:08 CEST |
BERGENBIO | BerGenBio ASA: New share capital registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 23 May 2024 17:15 CEST |
BERGENBIO | BerGenBio ASA - Minutes from the annual general meeting 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 May 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Invitation to first quarter 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2024 14:00 CEST |
BERGENBIO | BerGenBio ASA: Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2024 13:00 CEST |
BERGENBIO | BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 25 Apr 2024 12:55 CEST |
BERGENBIO | BerGenBio ASA: New share capital registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 17 Apr 2024 17:10 CEST |
BERGENBIO | BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission | 20103010 Biotechnology | Total number of voting rights and capital |
| 17 Apr 2024 09:42 CEST |
BERGENBIO | BerGenBio - Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 17 Apr 2024 08:16 CEST |
BERGENBIO | BerGenBio - Disclosure of large shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 16 Apr 2024 14:15 CEST |
BERGENBIO | BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Apr 2024 10:58 CEST |
BERGENBIO | BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates | 20103010 Biotechnology | Mandatory notification of trade primary insiders |